Kendal T. Ryter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kendal T. Ryter has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Jay T. Evans
Center for Translational Medicine, University of Montana, Missoula, USA
7 shared publications Cassandra Buhl
Center for Translational Medicine, 32 campus drive, Missoula, Montana 59812, United States
6 shared publicationsJay T. Evans
University of Montana 32 Campus Drive
5 shared publicationsGeorge Ettenger
Center for Translational Medicine, 32 campus drive, Missoula, Montana 59812, United States
4 shared publicationsRobert Child
Division of Biological Sciences, University of Montana, 32 Campus Drive, Missoula, MT 59812, United States
4 shared publicationsShannon M. Miller
University of Montana 32 Campus Drive
4 shared publications
Latest Publications
- 5 August 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (9) , 4466-4481
Self-Assembling Synthetic Trehalose Glycolipids for Mincle Activation: Biophysical Properties, Molecular Dynamics Simulations, and Vaccine Adjuvant Activity
Synthetic trehalose glycolipids (TGLs) that modulate the Macrophage Inducible C-Type Lectin receptor (Mincle) are attractive targets for adjuvant development. However, natural ligands such as trehalose dimycolate (TDM), as well as existing synthetic mimetics, are limited by poor physicochemical properties and reactogenicity, motivating the development of rationally designed synthetic TGLs. Herein, we investigated the biophysical properties of amphiphilic TGLs featuring hydrophobic, aromatic moieties attached to the polar trehalose headgroup via ester, amide, or triazole linkages. The formation of homogeneous and colloidally stable aqueous nanodispersions was readily achieved through focused ultrasonication, eliminating the need for cosolvents and/or surfactants that might interfere with the self-assembling and biological properties of these compounds. These self-assembled particles were characterized using DLS, cryo-TEM, and synchrotron small-angle X-ray scattering to gain insight into their particle morphology and liquid crystalline phase behavior. Additionally, molecular dynamics (MD) simulations were conducted to evaluate the critical packing parameter (CPP), a predictive descriptor of the supramolecular structures formed by self-assembling amphiphiles, under conditions that closely mimic experimental environments. The synthetic Mincle ligands formed lyotropic liquid crystals, including cubosomal or hexagonal phases as well as lamellar phases. In vitro and in vivo testing of these self-assemblies revealed that all tested TGLs exhibited measurable immunological activity. Analogues forming cubic phases were associated with comparatively stronger cytokine production and enhanced antigen-specific humoral and cell-mediated immune responses within this compound set. Taken together, the data support a model in which both molecular structure and supramolecular organization contribute to immunostimulatory activity, although these effects cannot be fully decoupled in the present study. Additionally, we developed an in silico model capable of predicting supramolecular assembly, providing insight into the self-assembly tendencies of trehalose-based amphiphiles, and offering broader relevance to other biologically active, self-assembling systems.
- 5 August 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (9) , 4466-4481
Self-Assembling Synthetic Trehalose Glycolipids for Mincle Activation: Biophysical Properties, Molecular Dynamics Simulations, and Vaccine Adjuvant Activity
Synthetic trehalose glycolipids (TGLs) that modulate the Macrophage Inducible C-Type Lectin receptor (Mincle) are attractive targets for adjuvant development. However, natural ligands such as trehalose dimycolate (TDM), as well as existing synthetic mimetics, are limited by poor physicochemical properties and reactogenicity, motivating the development of rationally designed synthetic TGLs. Herein, we investigated the biophysical properties of amphiphilic TGLs featuring hydrophobic, aromatic moieties attached to the polar trehalose headgroup via ester, amide, or triazole linkages. The formation of homogeneous and colloidally stable aqueous nanodispersions was readily achieved through focused ultrasonication, eliminating the need for cosolvents and/or surfactants that might interfere with the self-assembling and biological properties of these compounds. These self-assembled particles were characterized using DLS, cryo-TEM, and synchrotron small-angle X-ray scattering to gain insight into their particle morphology and liquid crystalline phase behavior. Additionally, molecular dynamics (MD) simulations were conducted to evaluate the critical packing parameter (CPP), a predictive descriptor of the supramolecular structures formed by self-assembling amphiphiles, under conditions that closely mimic experimental environments. The synthetic Mincle ligands formed lyotropic liquid crystals, including cubosomal or hexagonal phases as well as lamellar phases. In vitro and in vivo testing of these self-assemblies revealed that all tested TGLs exhibited measurable immunological activity. Analogues forming cubic phases were associated with comparatively stronger cytokine production and enhanced antigen-specific humoral and cell-mediated immune responses within this compound set. Taken together, the data support a model in which both molecular structure and supramolecular organization contribute to immunostimulatory activity, although these effects cannot be fully decoupled in the present study. Additionally, we developed an in silico model capable of predicting supramolecular assembly, providing insight into the self-assembly tendencies of trehalose-based amphiphiles, and offering broader relevance to other biologically active, self-assembling systems.
- Open Access
- 18 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10031
Systematic Evaluation of Regiochemistry and Lipidation of Aryl Trehalose Mincle Agonists
The Macrophage-Inducible C-type Lectin receptor (Mincle) plays a critical role in innate immune recognition and pathology, and therefore represents a promising target for vaccine adjuvants. Innovative trehalose-based Mincle agonists with improved pharmacology and potency may prove useful in the development of Th17-mediated adaptive immune responses. Herein, we report on in vitro and in silico investigations of specific Mincle ligand–receptor interactions required for the effective receptor engagement and activation of Th17-polarizing cytokines. Specifically, we employed a library of trehalose benzoate scaffolds, varying the degree of aryl lipidation and regiochemistry that produce inflammatory cytokines in a Mincle-dependent fashion. In vitro interleukin-6 (IL-6) cytokine production by human peripheral blood mononuclear cells (hPBMCs) indicated that the lipid regiochemistry is key to potency and maximum cytokine output, with the tri-substituted compounds inducing higher levels of IL-6 in hPBMCs than the di-substituted derivatives. Additionally, IL-6 production trended higher after stimulation with compounds that contained lipids ranging from five to eight carbons long, compared to shorter (below five) or longer (above eight) carbon chains, across all the substitution patterns. An analysis of the additional cytokines produced by hPBMCs revealed that compound 4d, tri-substituted and five carbons long, induced significantly greater levels of interleukin-1β (IL-1β), tumor necrosis factor- α (TNF-α), interleukin-23 (IL-23), and interferon- γ (IFN-γ) than the other compounds tested in this study. An in silico assessment of 4d highlighted the capability of this analogue to bind to the human Mincle carbohydrate recognition domain (CRD) efficiently. Together, these data highlight important structure–activity findings regarding Mincle-specific cytokine induction, generating a lead adjuvant candidate for future formulations and immunological evaluations.
- 18 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10031
Open AccessSystematic Evaluation of Regiochemistry and Lipidation of Aryl Trehalose Mincle Agonists
The Macrophage-Inducible C-type Lectin receptor (Mincle) plays a critical role in innate immune recognition and pathology, and therefore represents a promising target for vaccine adjuvants. Innovative trehalose-based Mincle agonists with improved pharmacology and potency may prove useful in the development of Th17-mediated adaptive immune responses. Herein, we report on in vitro and in silico investigations of specific Mincle ligand–receptor interactions required for the effective receptor engagement and activation of Th17-polarizing cytokines. Specifically, we employed a library of trehalose benzoate scaffolds, varying the degree of aryl lipidation and regiochemistry that produce inflammatory cytokines in a Mincle-dependent fashion. In vitro interleukin-6 (IL-6) cytokine production by human peripheral blood mononuclear cells (hPBMCs) indicated that the lipid regiochemistry is key to potency and maximum cytokine output, with the tri-substituted compounds inducing higher levels of IL-6 in hPBMCs than the di-substituted derivatives. Additionally, IL-6 production trended higher after stimulation with compounds that contained lipids ranging from five to eight carbons long, compared to shorter (below five) or longer (above eight) carbon chains, across all the substitution patterns. An analysis of the additional cytokines produced by hPBMCs revealed that compound 4d, tri-substituted and five carbons long, induced significantly greater levels of interleukin-1β (IL-1β), tumor necrosis factor- α (TNF-α), interleukin-23 (IL-23), and interferon- γ (IFN-γ) than the other compounds tested in this study. An in silico assessment of 4d highlighted the capability of this analogue to bind to the human Mincle carbohydrate recognition domain (CRD) efficiently. Together, these data highlight important structure–activity findings regarding Mincle-specific cytokine induction, generating a lead adjuvant candidate for future formulations and immunological evaluations.
- Open Access
- 6 June 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-15
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the top infectious killers in the world. The only licensed vaccine against TB, Bacille Calmette-Guérin (BCG), provides variable protection against pulmonary TB, especially in adults. Hence, novel TB vaccine approaches are urgently needed. Both Th1 and Th17 responses are necessary for protection against TB, yet effective adjuvants and vaccine delivery systems for inducing robust Th1 and Th17 immunity are lacking. Herein we describe a synthetic Mincle agonist, UM-1098, and a silica nanoparticle delivery system that drives Th1/Th17 responses to Mtb antigens. Stimulation of human peripheral blood mononuclear cells (hPBMCs) with UM-1098 induced high levels of Th17 polarizing cytokines IL-6, IL-1β, IL-23 as well as IL-12p70, IL-4 and TNF-α in vitro. PBMCs from both C57BL/6 and BALB/c mice responded with a similar cytokine pattern in vitro and in vivo. Importantly, intramuscular (I.M.) vaccination with UM-1098-adjuvanted TB antigen M72 resulted in significantly higher antigen-specific IFN-γ and IL-17A levels in C57BL/6 wt mice than Mincle KO mice. Vaccination of C57BL/6 wt mice with immunodominant Mtb antigens ESAT6/Ag85B or M72 resulted in predominantly Th1 and Th17 responses and induced antigen-specific serum antibodies. Notably, in a virulent Mtb challenge model, vaccination with UM-1098 adjuvanted ESAT6/Ag85B or M72 significantly reduced lung bacterial burden when compared with unvaccinated mice and protection occurred in the absence of pulmonary inflammation. These data demonstrate that the synthetic Mincle agonist UM-1098 induces strong Th1 and Th17 immunity after vaccination with Mtb antigens and provides protection against Mtb infection in mice.
- 6 June 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-15
Open AccessVaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the top infectious killers in the world. The only licensed vaccine against TB, Bacille Calmette-Guérin (BCG), provides variable protection against pulmonary TB, especially in adults. Hence, novel TB vaccine approaches are urgently needed. Both Th1 and Th17 responses are necessary for protection against TB, yet effective adjuvants and vaccine delivery systems for inducing robust Th1 and Th17 immunity are lacking. Herein we describe a synthetic Mincle agonist, UM-1098, and a silica nanoparticle delivery system that drives Th1/Th17 responses to Mtb antigens. Stimulation of human peripheral blood mononuclear cells (hPBMCs) with UM-1098 induced high levels of Th17 polarizing cytokines IL-6, IL-1β, IL-23 as well as IL-12p70, IL-4 and TNF-α in vitro. PBMCs from both C57BL/6 and BALB/c mice responded with a similar cytokine pattern in vitro and in vivo. Importantly, intramuscular (I.M.) vaccination with UM-1098-adjuvanted TB antigen M72 resulted in significantly higher antigen-specific IFN-γ and IL-17A levels in C57BL/6 wt mice than Mincle KO mice. Vaccination of C57BL/6 wt mice with immunodominant Mtb antigens ESAT6/Ag85B or M72 resulted in predominantly Th1 and Th17 responses and induced antigen-specific serum antibodies. Notably, in a virulent Mtb challenge model, vaccination with UM-1098 adjuvanted ESAT6/Ag85B or M72 significantly reduced lung bacterial burden when compared with unvaccinated mice and protection occurred in the absence of pulmonary inflammation. These data demonstrate that the synthetic Mincle agonist UM-1098 induces strong Th1 and Th17 immunity after vaccination with Mtb antigens and provides protection against Mtb infection in mice.
- 4 June 2024
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 7 (6) , 3877-3889
Promotion of Th17 Polarized Immunity via Co-Delivery of Mincle Agonist and Tuberculosis Antigen Using Silica Nanoparticles
Adjuvants and immunomodulators that effectively drive a Th17-skewed immune response are not part of the standard vaccine toolkit. Vaccine adjuvants and delivery technologies that can induce Th17 or Th1/17 immunity and protection against bacterial pathogens, such as tuberculosis (TB), are urgently needed. Th17-polarized immune response can be induced using agonists that bind and activate C-type lectin receptors (CLRs) such as macrophage inducible C-type lectin (Mincle). A simple but effective strategy was developed for codelivering Mincle agonists with the recombinant Mycobacterium tuberculosis fusion antigen, M72, using tunable silica nanoparticles (SNP). Anionic bare SNP, hydrophobic phenyl-functionalized SNP (P-SNP), and cationic amine-functionalized SNP (A-SNP) of different sizes were coated with three synthetic Mincle agonists, UM-1024, UM-1052, and UM-1098, and evaluated for adjuvant activity in vitro and in vivo. The antigen and adjuvant were coadsorbed onto SNP via electrostatic and hydrophobic interactions, facilitating multivalent display and delivery to antigen presenting cells. The cationic A-SNP showed the highest coloading efficiency for the antigen and adjuvant. In addition, the UM-1098-adsorbed A-SNP formulation demonstrated slow-release kinetics in vitro, excellent stability over 12 months of storage, and strong IL-6 induction from human peripheral blood mononuclear cells. Co-adsorption of UM-1098 and M72 on A-SNP significantly improved antigen-specific humoral and Th17-polarized immune responses in vivo in BALB/c mice relative to the controls. Taken together, A-SNP is a promising platform for codelivery and proper presentation of adjuvants and antigens and provides the basis for their further development as a vaccine delivery platform for immunization against TB or other diseases for which Th17 immunity contributes to protection.
- 4 June 2024
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 7 (6) , 3877-3889
Promotion of Th17 Polarized Immunity via Co-Delivery of Mincle Agonist and Tuberculosis Antigen Using Silica Nanoparticles
Adjuvants and immunomodulators that effectively drive a Th17-skewed immune response are not part of the standard vaccine toolkit. Vaccine adjuvants and delivery technologies that can induce Th17 or Th1/17 immunity and protection against bacterial pathogens, such as tuberculosis (TB), are urgently needed. Th17-polarized immune response can be induced using agonists that bind and activate C-type lectin receptors (CLRs) such as macrophage inducible C-type lectin (Mincle). A simple but effective strategy was developed for codelivering Mincle agonists with the recombinant Mycobacterium tuberculosis fusion antigen, M72, using tunable silica nanoparticles (SNP). Anionic bare SNP, hydrophobic phenyl-functionalized SNP (P-SNP), and cationic amine-functionalized SNP (A-SNP) of different sizes were coated with three synthetic Mincle agonists, UM-1024, UM-1052, and UM-1098, and evaluated for adjuvant activity in vitro and in vivo. The antigen and adjuvant were coadsorbed onto SNP via electrostatic and hydrophobic interactions, facilitating multivalent display and delivery to antigen presenting cells. The cationic A-SNP showed the highest coloading efficiency for the antigen and adjuvant. In addition, the UM-1098-adsorbed A-SNP formulation demonstrated slow-release kinetics in vitro, excellent stability over 12 months of storage, and strong IL-6 induction from human peripheral blood mononuclear cells. Co-adsorption of UM-1098 and M72 on A-SNP significantly improved antigen-specific humoral and Th17-polarized immune responses in vivo in BALB/c mice relative to the controls. Taken together, A-SNP is a promising platform for codelivery and proper presentation of adjuvants and antigens and provides the basis for their further development as a vaccine delivery platform for immunization against TB or other diseases for which Th17 immunity contributes to protection.
- 9 January 2023
- Published by Elsevier in Tetrahedron
- Vol. 132
Synthesis and biological evaluation of trehalose-based Bi-aryl derivatives as C-type lectin ligands
- 9 January 2023
- Published by Elsevier in Tetrahedron
- Vol. 132
Synthesis and biological evaluation of trehalose-based Bi-aryl derivatives as C-type lectin ligands
- Open Access
- 4 July 2022
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 54 (14)
Linked PDF of Table of Contents
Article published online: 04 July 2022 Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 4 July 2022
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 54 (14)
Open AccessLinked PDF of Table of Contents
Article published online: 04 July 2022 Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 9 February 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (8) , 1246-1251
Design of Trehalose‐Based Amide/Sulfonamide C‐type Lectin Receptor Signaling Compounds
Mincle agonists have been shown to induce inflammatory cytokine production, such as tumor necrosis factor‐alpha (TNF) and promote the development of a Th1/Th17 immune response that might be crucial to development of effective vaccination against pathogens such as Mycobacterium tuberculosis. As an expansion of our previous work, a library of 6,6′‐amide and sulfonamide α,α‐d‐trehalose compounds with various substituents on the aromatic ring was synthesized efficiently in good to excellent yields. These compounds were evaluated for their ability to activate the human C‐type lectin receptor Mincle by the induction of cytokines from human peripheral blood mononuclear cells. A preliminary structure–activity relationship (SAR) of these novel trehalose diamides and sulfonamides revealed that aryl amide‐linked trehalose compounds demonstrated improved activity and relatively high potency cytokine production compared to the Mincle ligand trehalose dibehenate adjuvant (TDB) and the natural ligand trehalose dimycolate (TDM) inducing dose‐dependent and human‐Mincle‐specific stimulation in a HEK reporter cell line.
- 9 February 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (8) , 1246-1251
Design of Trehalose‐Based Amide/Sulfonamide C‐type Lectin Receptor Signaling Compounds
Mincle agonists have been shown to induce inflammatory cytokine production, such as tumor necrosis factor‐alpha (TNF) and promote the development of a Th1/Th17 immune response that might be crucial to development of effective vaccination against pathogens such as Mycobacterium tuberculosis. As an expansion of our previous work, a library of 6,6′‐amide and sulfonamide α,α‐d‐trehalose compounds with various substituents on the aromatic ring was synthesized efficiently in good to excellent yields. These compounds were evaluated for their ability to activate the human C‐type lectin receptor Mincle by the induction of cytokines from human peripheral blood mononuclear cells. A preliminary structure–activity relationship (SAR) of these novel trehalose diamides and sulfonamides revealed that aryl amide‐linked trehalose compounds demonstrated improved activity and relatively high potency cytokine production compared to the Mincle ligand trehalose dibehenate adjuvant (TDB) and the natural ligand trehalose dimycolate (TDM) inducing dose‐dependent and human‐Mincle‐specific stimulation in a HEK reporter cell line.
- 1 July 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (14) , 115564
6,6′-Aryl trehalose analogs as potential Mincle ligands
- 1 July 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (14) , 115564
6,6′-Aryl trehalose analogs as potential Mincle ligands
- 6 December 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (1) , 309-320
Aryl Trehalose Derivatives as Vaccine Adjuvants for Mycobacterium tuberculosis
Mycobacterium tuberculosis (Mtb) continues to be a major health threat worldwide, and the development of Mtb vaccines could play a pivotal role in the prevention and control of this devastating epidemic. Th17-mediated immunity has been implicated in disease protection correlates of immune protection against Mtb. Currently, there are no approved adjuvants capable of driving a Th17 response in a vaccine setting. Recent clinical trial results using trehalose dibehenate have demonstrated a formulation-dependant proof of concept adjuvant system CAF01 capable of inducing long-lived protection. We have discovered a new class of Th17-inducing vaccine adjuvants based on the natural product Brartemicin. We synthesized and evaluated the capacity of a library of aryl trehalose derivatives to drive immunostimulatory reresponses and evaluated the structure–activity relationships in terms of the ability to engage the Mincle receptor and induce production of innate cytokines from human and murine cells. We elaborated on the structure–activity relationship of the new scaffold and demonstrated the ability of the lead entity to induce a pro-Th17 cytokine profile from primary human peripheral blood mononuclear cells and demonstrated efficacy in generating antibodies in combination with tuberculosis antigen M72 in a mouse model.
- 6 December 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (1) , 309-320
Aryl Trehalose Derivatives as Vaccine Adjuvants for Mycobacterium tuberculosis
Mycobacterium tuberculosis (Mtb) continues to be a major health threat worldwide, and the development of Mtb vaccines could play a pivotal role in the prevention and control of this devastating epidemic. Th17-mediated immunity has been implicated in disease protection correlates of immune protection against Mtb. Currently, there are no approved adjuvants capable of driving a Th17 response in a vaccine setting. Recent clinical trial results using trehalose dibehenate have demonstrated a formulation-dependant proof of concept adjuvant system CAF01 capable of inducing long-lived protection. We have discovered a new class of Th17-inducing vaccine adjuvants based on the natural product Brartemicin. We synthesized and evaluated the capacity of a library of aryl trehalose derivatives to drive immunostimulatory reresponses and evaluated the structure–activity relationships in terms of the ability to engage the Mincle receptor and induce production of innate cytokines from human and murine cells. We elaborated on the structure–activity relationship of the new scaffold and demonstrated the ability of the lead entity to induce a pro-Th17 cytokine profile from primary human peripheral blood mononuclear cells and demonstrated efficacy in generating antibodies in combination with tuberculosis antigen M72 in a mouse model.
- Open Access
- 28 February 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 338
Species-Specific Structural Requirements of Alpha-Branched Trehalose Diester Mincle Agonists
Despite the ever present need for an effective Mycobacterium tuberculosis (Mtb) vaccine, efforts for development have been largely unsuccessful. Correlates of immune protection against Mtb are not wholly defined, but Th1 and likely Th17 adaptive immune responses have been demonstrated to be necessary for vaccine-mediated protection. Unfortunately, no approved adjuvants are able to drive a Th17 response, though recent clinical trials with CAF01 have demonstrated proof of concept. Herein we present the discovery and characterization of a new class of potential Th17-inducing vaccine adjuvants, alpha-branched trehalose diester molecules (αTDE). Based off the Mtb immunostimulatory component trehalose dimycolate (TDM), we synthesized and evaluated the immunostimulatory capacity of a library of structural derivatives. We evaluated the structure activity relationship of the compounds in relation to chain length and engagement of the Mincle receptor, production of innate cytokines from human and murine cells, and a pro-Th17 cytokine profile from primary human peripheral blood mononuclear cells. Murine cells displayed more structural tolerance, engaging and responding to a wide array of compound chain lengths. Interestingly, human cells displayed a unique specificity for ester chains between 5 and 14 carbons for maximal immune stimulating activity. Evaluation of two distinct αTDEs, B16 and B42, in concert with a recombinant Mtb antigen demonstrated their ability to augment a Th17 immune response against a Mtb antigen in vivo. Collectively this data describes the species-specific structural requirements for maximal human activity of alpha-branched trehalose diester compounds and demonstrates their capacity to serve as potent Th17-inducing adjuvants.
- 28 February 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 338
Open AccessSpecies-Specific Structural Requirements of Alpha-Branched Trehalose Diester Mincle Agonists
Despite the ever present need for an effective Mycobacterium tuberculosis (Mtb) vaccine, efforts for development have been largely unsuccessful. Correlates of immune protection against Mtb are not wholly defined, but Th1 and likely Th17 adaptive immune responses have been demonstrated to be necessary for vaccine-mediated protection. Unfortunately, no approved adjuvants are able to drive a Th17 response, though recent clinical trials with CAF01 have demonstrated proof of concept. Herein we present the discovery and characterization of a new class of potential Th17-inducing vaccine adjuvants, alpha-branched trehalose diester molecules (αTDE). Based off the Mtb immunostimulatory component trehalose dimycolate (TDM), we synthesized and evaluated the immunostimulatory capacity of a library of structural derivatives. We evaluated the structure activity relationship of the compounds in relation to chain length and engagement of the Mincle receptor, production of innate cytokines from human and murine cells, and a pro-Th17 cytokine profile from primary human peripheral blood mononuclear cells. Murine cells displayed more structural tolerance, engaging and responding to a wide array of compound chain lengths. Interestingly, human cells displayed a unique specificity for ester chains between 5 and 14 carbons for maximal immune stimulating activity. Evaluation of two distinct αTDEs, B16 and B42, in concert with a recombinant Mtb antigen demonstrated their ability to augment a Th17 immune response against a Mtb antigen in vivo. Collectively this data describes the species-specific structural requirements for maximal human activity of alpha-branched trehalose diester compounds and demonstrates their capacity to serve as potent Th17-inducing adjuvants.